Incidence and Predictors of an Abnormal Liver Function Test Among 674 Systemic Sclerosis Patients: A Cohort Study
Kookwan Sawadpanich,Palinee Promasen,Pisaln Mairiang,Wattana Sukeepaisarnjareon,Apichat Sangchan,Tanita Suttichaimongkol,Kawin Tangvoraphonkchai,Chingching Foocharoen
DOI: https://doi.org/10.2147/OARRR.S410165
2023-05-16
Open Access Rheumatology: Research and Reviews
Abstract:Kookwan Sawadpanich, 1 Palinee Promasen, 1 Pisaln Mairiang, 1 Wattana Sukeepaisarnjareon, 1 Apichat Sangchan, 1 Tanita Suttichaimongkol, 1 Kawin Tangvoraphonkchai, 1 Chingching Foocharoen 2 1 Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand; 2 Division of Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand Correspondence: Chingching Foocharoen, Division of Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand, Tel +66-43-363-746 ; +66-43-363-664, Email Background: Abnormal liver function tests (LFTs) can indicate cirrhosis or liver cancer leading to mortality among systemic sclerosis (SSc) patients. No recent studies have investigated the clinical predictors of an abnormal LFT in SSc. We aimed to determine the incidence of abnormal LFT (including from hepatitis and cholestasis) and to identify its clinical predictors in SSc patients. Methods: An historical cohort was conducted on 674 adult SSc patients who attended the Scleroderma Clinic, Khon Kaen University, between January 2012 and November 2019 and who underwent routine screening for LFT. A Cox regression was used to analyze the clinical predictors of abnormal LFT. Results: Four hundred and thirty cases, representing 4190 person-years, had abnormal LFTs (viz, from hepatitis, cholestasis, and cholestatic hepatitis) for an incidence rate of 10.2 per 100 person-years. The respective incidence of hepatitis, cholestasis, and cholestatic hepatitis was 20.5, 12.9, and 20.4 per 100 person-years. The respective median first-time detection of hepatitis, cholestasis, and cholestatic hepatitis was 3.0, 5.9, and 2.8 years, and none had signs or symptoms suggestive of liver disease. According to the Cox regression analysis, the predictors of an abnormal LFT in SSc were elderly onset of SSc (hazard ratio (HR) 1.02), alcoholic drinking (HR 1.74), high modified Rodnan Skin Score (mRSS) (HR 1.03), edematous skin (HR 2.94), Raynaud's phenomenon (HR 1.39), hyperCKaemia (HR 1.88), and methotrexate use (HR 1.55). In contrast, current sildenafil treatment (HR 0.63) and high serum albumin (HR 0.70) were protective factors. Conclusion: Occult hepatitis, cholestasis, and cholestatic hepatitis can be detected in SSc patients using LFT screening, especially in cases of early disease onset. The long-term outcome is uncertain, and more longitudinal research is required. Keywords: systemic sclerosis, scleroderma, scleroderma and related disorders, hepatitis, cholestasis, cholestatic hepatitis, abnormal liver function test, liver, cohort study Systemic sclerosis (SSc) is an immune system disorder that can include complications of liver disease with or without symptoms. Previous clinical studies reported abnormal liver function tests (LFTs) in SSc patients ranging from 1% to 37%, 1,2 with cholestasis being the most common, followed by hepatitis. 3 Long-lasting drug-induced liver injury, active organ involvement, and fatty liver 2 can induce liver fibrosis and cirrhosis. 2,4 In most cases, cholestasis or hepatitis in scleroderma do not progress to the point of requiring a liver transplant or death. 5 Abnormal liver function tests have been reported among SSc patients since 1934, and primary biliary cholangitis (PBC) is a leading cause of liver disease in SSc. 6 Primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) have also been reported in SSc, but their prevalence is relatively rare. 7–14 Owing to the various causes of abnormal LFT, the etiologies of abnormal LFT other than those related to autoimmune diseases like SSc—like alcohol consumption and hepatotoxic agents—should be ruled out. 8,15–18 Once hepatitis or cholestasis has developed, cirrhosis and its complications (liver cancer) can ensue. 19 Previous reports revealed that the prevalence of liver cancer among SSc patients was higher than in the normal population. The respective standardized incidence ratio of liver cancer in female and male SSc patients was 20 and 16 times greater than the general population without any association with specific autoantibodies of SSc (viz., the anti-U1 RNP, anti-Scl70, or anti-centromere antibodies). 5 Proper screening of LFT might be beneficial for the early detection of liver cancer, particularly in SSc patients at high risk of developing liver cancer. Currently, there is a lack of research on (a) how often LFT screening should be performed in SSc patients and (b) the risk association or predictors (i -Abstract Truncated-